Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term randomized trial. Found 57 abstracts

no pagination
Salama JK, Saba N, Quon H, Garg MK, Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ, Expert Panel Radiation O. ACR appropriateness criteria (R) adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncology. 2011 Jul;47(7):554-9.   PMCID: not NIH funded
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU international. 2010 Aug;106(3):357-61.   PMCID: *
Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024. Journal of Clinical Oncology. 2009 Oct;27(28):4727-32.   PMCID: PMC2754914
Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ, Movsas B, Byhardt RW. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. Journal of Clinical Oncology. 2005 Aug;23(22):4991-8.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. International Journal of Radiation Oncology Biology Physics. 2005 Jun;62(2):397-405.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. International Journal of Radiation Oncology Biology Physics. 2005 Mar;61(3):695-701.
Forastiere AA, Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, Hicks WL, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A, Urba S, Weymuller EA, Wheeler RH, Wolf GT. NCCN Practice Guidelines for head and neck cancers. Oncology-New York. 2000 Nov;14(11A):163-94.
Eifel PJ, Moughan J, Owen J, Katz A, Mahon I, Hanks GE. Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: Patterns of care study. International Journal of Radiation Oncology Biology Physics. 1999 Jan 15;43(2):351-8.
Garay CA, Engstrom PF. Chemoprevention of colorectal cancer: Dietary and pharmacologic approaches. Oncology-New York. 1999 Jan;13(1):89-97.
Langer CJ. Induction or neoadjuvant therapy in resectable non-small cell lung cancer. Seminars in Oncology. 1999 Oct;26(5):34-9.
Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Seminars in Radiation Oncology. 1999 Apr;9(2):108-16.
Levy MH. NCCN task force report: Supportive and palliative care. Oncology-New York. 1999 Nov;13(11A):517-22.
McGuire WP, Brady MF, Ozols RF. The Gynecologic Oncology Group experience in ovarian cancer. Annals of Oncology. 1999 Jan;10:29-34.
Miller SM, Fang CY, Manne SL, Engstrom PF, Daly MB. Decision making about prophylactic oophorectomy among at-risk women: Psychological influences and implications. Gynecologic Oncology. 1999 Dec;75(3):406-12.
Ozols RF, Gore M, Trope C, Grenman S. Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Annals of Oncology. 1999 Jan;10:59-64.
Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, Falkson G, Falkson HC, Taylor SG, Tormey DC. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 1999 Jun;17(6):1689-700.
Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. Journal of Clinical Oncology. 1999 Jul;17(7):2198-207.
Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Seminars in Oncology. 1998 Jun;25(3):326-34.
Malone MD, Barber L, Comerota AJ. Clinical applications of thrombolytic therapy for arterial and graft occlusion. Surgical Clinics of North America. 1998 Aug;78(4):647-+.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term randomized trial

randomized trial carcinoma cancer radiotherapy cisplatin therapy chemotherapy phase-ii locally advanced head stage-iii phase-iii trial cyclophosphamide surgery taxol gynecologic-oncology-group postoperative radiation-therapy adjuvant adenocarcinoma survival sensitizer suppression neoadjuvant prostate cancer radiation irradiation locally advanced-carcinoma cell support definitive radiotherapy squamous-cell carcinoma eortc vitamin-e ovarian cancer risk receptor bone-marrow transplantation environmental factors phase- platinum-resistant colony-stimulating factor concurrent chemotherapy positive breast-cancer treatment time prospective breast-cancer risk axillary iiib prolongation postoperative responses taxanes information node-positive head clot lysis genitourinary morbidity immunotherapy distress fibrinolytic therapy escalation 2nd- androgen suppression Prostate cancer hormones susceptibility ovarian cancer ovarian-cancer oral tongue chemotherapy regimens neoadjuvant hormonal-therapy platinum modified radical-mastectomy Chemoradiotherapy prophylactic oophorectomy dose-response reproductive factors high risk intensive therapy 3D-CRT deprivation therapy Mycobacterium bovis urinary-bladder vitamins radiation-therapy dose intensity hormone replacement cervix cancer transplantation colon-cancer chemoradiotherapy head and neck low-dose streptokinase urothelial cell hyperfractionated radiation-therapy breast-cancer risk metaanalysis peripheral vascular-disease combination chemotherapy new drugs transitional-cell carcinoma peripheral stem cell pelvic blunting autologous bone marrow transplantation look laparotomy Post-operative radiotherapy head and neck pro- late rectal toxicity iowa womens health in-situ doxorubicin conventional fractionation gastrointestinal local bypass grafts conformal radiation-therapy adjuvant therapy rectal polyps Intensity-modulated radiotherapy glottic cancer 3-hour infusion Head and neck cancer recurrence vp-16 concurrent radiation group protocol 92-02 dose-escalation trial familial adenomatous polyposis oncology group rtog Post-operative BCG intravenous expression external-beam radiotherapy time Adjuvant head and neck follow-up style disease Appropriateness criteria premenopausal women intraperitoneal therapy fluorouracil familial ovarian-cancer oral-contraceptive use Gastrointestinal toxicity urokinase curves regional recurrence monitoring vs iii epithelial-cell proliferation margins
Last updated on Friday, January 03, 2020